Emily Minkow
Managing Director·RA Capital Management
Emily Minkow is a Managing Director on RA Capital's Venture Team, where she leads venture-stage investments. She previously spent three years as a Venture Partner at Raven focused on creating and leading new biotech companies, including serving as Interim CEO of Stylus Medicine and Consulting Chief Business Officer of Aliada Therapeutics through its acquisition by AbbVie. Before RA Capital, she was Chief Business Officer of Prevail Therapeutics from inception through its IPO and acquisition by Eli Lilly, and earlier held business development and marketing roles at Celgene.
See the rest of Emily Minkow's profile.
Deal history, investment focus, outreach angles and the rest of the background. One email, no password — we send a link and you land right back here.